SCHEMBL5065474

SCHEMBL5065474

CSc1ncc2cc(-c3ccc(F)c(NC(=O)Nc4cccc(-c5ccccc5)c4)c3)c(=O)n(C)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 9/20 0.45
RIPK1 Q13546 2/20 0.43
NTRK1 P04629 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
KDR P35968 2/20 0.41
SRC P12931 3/20 0.40
PDGFRB P09619 2/20 0.39
ABL1 P00519 1/20 0.39
PDGFRA P16234 1/20 0.39
MAPK14 Q16539 1/20 0.39
EGFR P00533 1/20 0.39
FGFR1 P11362 1/20 0.39
FGFR2 P21802 1/20 0.39
FGFR4 P22455 1/20 0.39
FGFR3 P22607 1/20 0.39
SYK P43405 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5065413 0.94 NTRK1 (0.45) WEE1NTRK1MAPTKDRSRC
SCHEMBL4552420 0.89 BRAF (0.41) WEE1RIPK1KDRSRCPDGFRB
SCHEMBL4565838 0.89 SYK (0.46) WEE1RIPK1MAPTKDRSRC
SCHEMBL5061511 0.88 WEE1 (0.51) WEE1KDRSRCPDGFRBABL1
SCHEMBL5057551 0.88 WEE1 (0.41) WEE1NTRK1KDM4EALDH1A1MAPT
SCHEMBL5057488 0.85 NTRK1 (0.41) WEE1NTRK1MAPTRAB9AKDR
SCHEMBL5057707 0.83 KDR (0.44) KDRSRCPDGFRBABL1
SCHEMBL4419493 0.83 BRAF (0.40) WEE1NTRK1MAPTRAB9AKDR
SCHEMBL5057392 0.83 BRAF (0.40) WEE1NTRK1KDRSRCPDGFRB
SCHEMBL5057565 0.82 BRAF (0.40) WEE1NTRK1ALDH1A1KDRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 WEE1 363/4885RIPK1 151/4885NTRK1 131/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 WEE1 363/4885RIPK1 151/4885NTRK1 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.